BioSpace News Archive

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced submission to the European Medicines Agency (EMA) of a variation application to the Marketing Authorization for LIVMARLI® (maralixibat) oral solution, to extend the label for progressive familial intrahepatic cholestasis (PFIC) in patients two months of age and older.

Celularity Inc. announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 9,230,770 shares of its Class A common stock together with warrants to purchase up to 9,230,770 shares of its Class A common stock at a combined purchase price of $0.65 per share and accompanying warrant.

The Cystic Fibrosis Foundation announced that Yvonne Massenburg will join the organization as its next Chief People Officer.

RELIEF THERAPEUTICS Holding SA announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities.

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million.

Aurinia Pharmaceuticals Inc. announced promising results from the AURORA Renal Biopsy Sub-Study.

Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

CareDx, Inc. and Miromatrix Medical Inc. announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.

Oculis Holding AG announces that members of management will be participating in the following April investor conferences.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that its Annual Report for 2022 has been published.